Market closedNon-fractional
Janux Therapeutics/JANX
13:30
14:25
15:15
16:10
17:00
1D1W1MYTD1YMAX
About Janux Therapeutics
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Ticker
JANX
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology
Headquarters
San Diego, United States
Employees
68
Website
www.januxrx.com
JANX Metrics
BasicAdvanced
$2B
Market cap
-
P/E ratio
-$1.21
EPS
3.87
Beta
-
Dividend rate
Price and volume
Market cap
$2B
Beta
3.87
Financial strength
Current ratio
62.086
Quick ratio
61.851
Long term debt to equity
3.448
Total debt to equity
3.688
Management effectiveness
Return on assets (TTM)
-8.74%
Return on equity (TTM)
-11.50%
Valuation
Price to revenue (TTM)
247.21
Price to book
3.1
Price to tangible book (TTM)
3.1
Price to free cash flow (TTM)
-33.82
Growth
Revenue change (TTM)
-19.67%
Earnings per share change (TTM)
-24.85%
3-year revenue growth
167.66%
3-year earnings per share growth
-46.11%
What the Analysts think about JANX
Analyst Ratings
Majority rating from 9 analysts.
JANX Financial Performance
Income StatementBalance sheetCash Flow
Income Statement
Revenues and expenses
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$1.2M
-50.00%
Net income
-$15M
25.64%
Profit margin
-1,225.00%
151.28%
JANX Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.42
-$0.25
-$0.25
-$0.30
-
Expected
-$0.52
-$0.47
-$0.41
-$0.33
-$0.32
Surprise
-18.84%
-46.81%
-39.05%
-9.43%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon
Market closedNon-fractional
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Janux Therapeutics stock?
Janux Therapeutics (JANX) has a market cap of $2B as of July 05, 2024.
What is the P/E ratio for Janux Therapeutics stock?
The price to earnings (P/E) ratio for Janux Therapeutics (JANX) stock is 0 as of July 05, 2024.
Does Janux Therapeutics stock pay dividends?
No, Janux Therapeutics (JANX) stock does not pay dividends to its shareholders as of July 05, 2024.
When is the next Janux Therapeutics dividend payment date?
Janux Therapeutics (JANX) stock does not pay dividends to its shareholders.
What is the beta indicator for Janux Therapeutics?
Janux Therapeutics (JANX) has a beta rating of 3.87. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.
Buy or sell Janux Therapeutics stock
Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.